CompletedNot applicableNCT00248547
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OHSU Knight Cancer Institute
- Principal Investigator
- Joseph Bubalo, PharmDOHSU Knight Cancer Institute
- Intervention
- aprepitant(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2009
Study locations (1)
- OHSU Knight Cancer Institute, Portland, Oregon, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00248547 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.